A FDA advisory panel concluded that a Biogen treatment for a rare, genetic form of ALS should be conditionally approved, despite unanswered questions.
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Biocon is developing a generic version of Novo Nordisk’s Wegovy and is prepared to conduct a clinical trial next year if needed.
BIO’s about-face in its relationship with WuXi AppTec illustrates the difficulty the biotech industry faces in dealing with an issue that is moving fast and…
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week…
A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.
Colorado lawmakers are abandoning a bill that would have required a new state board — chartered with setting caps for the cost of medicines — to…
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal…
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s…
